Maravai LifeSciences Holdings Inc. Class A Common Stock vs Stanley Black & Decker, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Stanley Black & Decker, Inc. trades at $89.91 (market cap $13.70B). The key difference: Stanley Black & Decker, Inc. is far larger — about 14.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Stanley Black & Decker, Inc. pays a 3.7% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| MRVI | SWK | |
|---|---|---|
Market Cap | $972.90M | $13.70B |
Volume | 4,325,710 | 1,098,669 |
Sector | Health | Industrials |
52-Week High | $9.00 | $104.00 |
52-Week Low | $2.83 | $62.12 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $1.08B | $17.86B |
Dividend Yield | — | 3.7% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Stanley Black & Decker (SWK) trades at $90.29, up 1.85% today, with a bearish technical signal from moving averages despite recent earnings beats. The company shows improving profitability with a net income margin of 4.07% in 2025, and revenue is projected to grow to $15.2B in 2026. Recent news highlights product launches like the dustbuster mini and management's focus on margin gains and brand strength.
The outlook is cautiously optimistic with a consensus price target of $93.00, offering modest upside. Key risks include competitive pressures and execution challenges, but strong institutional buying and a dividend history support long-term value. Investors should weigh improving fundamentals against near-term technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →